Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IP6X
|
|||
| Former ID |
DCL000191
|
|||
| Drug Name |
Osanetant
|
|||
| Synonyms |
Osanetant [INN]; SR-142801; UNII-K7G81N94DT; SB-236984; SR-142806; SR142801; SR-14280; K7G81N94DT; CHEMBL346178; 160492-56-8; SR 142801; N-(1-(3-((R)-1-Benzoyl-3-(3,4-dichlorophenyl)-3-piperidyl)propyl)-4-phenyl-4-piperidyl)-N-methylacetamide; n-(1-{3-[(3r)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl)-n-methylacetamide; N-(1-(3-((3R)-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl)propyl)-4-phenyl-4-piperidinyl)-N-methylacetamide; [3H]osanetant; Osanetant [INN]; N-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]-N-methylacetamide; N-(1-{3-[(3r)-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl)-n-methylacetamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizoaffective disorder [ICD-11: 6A21] | Discontinued in Phase 2b | [1], [2] | |
| Schizophrenia [ICD-11: 6A20] | Discontinued in Phase 2b | [1], [2] | ||
| Depression [ICD-11: 6A70-6A7Z; ICD-9: 311] | Terminated | [1], [2] | ||
| Company |
Sanofi-aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C35H41Cl2N3O2
|
|||
| Canonical SMILES |
CC(=O)N(C)C1(CCN(CC1)CCCC2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5
|
|||
| InChI |
1S/C35H41Cl2N3O2/c1-27(41)38(2)35(29-13-7-4-8-14-29)19-23-39(24-20-35)21-9-17-34(30-15-16-31(36)32(37)25-30)18-10-22-40(26-34)33(42)28-11-5-3-6-12-28/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3/t34-/m0/s1
|
|||
| InChIKey |
DZOJBGLFWINFBF-UMSFTDKQSA-N
|
|||
| CAS Number |
CAS 160492-56-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9374273, 14765045, 14789447, 30422444, 47583780, 48329110, 50068883, 50070629, 50182021, 57304375, 57399839, 85286118, 90342450, 103399782, 103831276, 104132813, 113468548, 117463754, 126671662, 127809701, 134338860, 135650780, 137265093, 137275954, 141237279, 144116320, 152035367, 164780141, 175426879, 178100471, 198978083, 223660710, 223704871, 226491182, 252160228
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neuromedin-K receptor (TACR3) | Target Info | Antagonist | [3], [4], [5], [6] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Reactome | G alpha (q) signalling events | |||
| WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2110). | |||
| REF 2 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
| REF 3 | Pharmacological characterization of senktide-induced tail whips. Neuropharmacology. 2010 Jan;58(1):259-67. | |||
| REF 4 | The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils. Eur J Pharmacol. 2008 Dec 14;600(1-3):87-92. | |||
| REF 5 | Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412). Neuropharmacology. 2009 Feb;56(2):342-9. | |||
| REF 6 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 362). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.